Cangrelor tetrasodium

产品说明书

Print
Chemical Structure| 163706-36-3 同义名 : AR-C69931MX tetrasodium;Cangrelor (sodium salt);AR-C69931MX
CAS号 : 163706-36-3
货号 : A605340
分子式 : C17H21Cl2F3N5Na4O12P3S2
纯度 : 99%+
分子量 : 864.287
MDL号 : MFCD14635359
存储条件：

粉末 Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 12 mg/mL(13.88 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 120 mg/mL(138.84 mM)，配合低频超声助溶
动物实验配方：
生物活性
靶点

  • P2Y receptor
描述 Cangrelor is the only currently available intravenous platelet P2Y12 receptor inhibitor, and its quick onset and offset make it an appealing option for antiplatelet therapy[1]. In vitro, the experiment focused on αIIbβ3 complex (platelet receptor for fibrinogen), and cangrelor (140μM, 15 min) suppressed the expression of this surface membrane activation marker in platelets[2]. Cangrelor tetrasodium (10 mg/kg) not only significantly decreases BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreases the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice[3].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03182855 Acute Coronary Syndrome ... 展开 >> Myocardial Infarction STEMI - ST Elevation Myocardial Infarction 收起 << Phase 4 Not yet recruiting August 1, 2019 Denmark ... 展开 >> Aarhus University Hospital Not yet recruiting Aarhus, Denmark, 8200 Contact: Jacob Thorsted Sorensen, MD, PhD    +4540143563    jacsoe@rm.dk    Contact: Steen D Kristensen, MD, DMSc    +4530922336    stekrist@rm.dk 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.16mL

0.23mL

0.12mL

5.79mL

1.16mL

0.58mL

11.57mL

2.31mL

1.16mL
参考文献

[1]De Luca L, Steg PG, Bhatt DL, Capodanno D, Angiolillo DJ. Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. J Am Heart Assoc. 2021;10(13):e022125.

[2]Kassassir H, Siewiera K, Sychowski R, Watała C. Can the antiplatelet effects of cangrelor be reliably studied in mice under in vivo and in vitro conditions using flow cytometry?. Pharmacol Rep. 2013;65(4):870-883.

[3]Zhan T, Wei T, Dong L, et al. Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice. Mol Immunol. 2020;120:83-92.